Jianhai Tech Completes Nearly 100 Million Yuan Series A+ Financing Led by Sherpa Healthcare Partners with Strategic Investment from iFLYTEK

VCBeat (WeChat ID: vcbeat) has learned that Hangzhou Jianhai Science and Technology Co., Ltd. (“Jianhai Tech”) has closed its nearly RMB 100 million Series A+ financing round. The round was led by Sherpa Healthcare Partners, with strategic investment from iFlytek and follow-on investments from existing shareholders Haibang and Lihan. Probe Capital served as the exclusive financial advisor for this financing round.

Founded in 2015, Jianhai Technology is a company that provides healthcare informatics and medical health services through AI. It is committed to leveraging AI to assist hospitals in patient condition tracking and care journey management, making follow-up visits a prescribed intervention.

“Currently, the patient follow-up market is still in its nascent stage,” said Wang Jian, CEO of Hangzhou Jianhai Science and Technology Co., Ltd. However, driven by the urgent need to improve doctor-patient relationships, the acceleration of health insurance reforms, and the upgrading of patients’ demand for medical services, the market is poised for rapid growth, with its size projected to reach RMB 50 billion by 2026.

Driven by market trends, Jianhai Technology has developed an intelligent AI follow-up system, with its core advantage lying in its AI technology—the Jishi Brain. It features intelligent assisted interaction, intelligent assisted judgment, and an intelligent assisted processing engine, integrating technologies such as deep learning, big data processing, speech synthesis, recognition, and analysis. Through channels like telephone and WeChat, it assists medical staff in completing tasks such as hospital follow-ups, satisfaction surveys, follow-up visit reminders, and chronic disease management.

Currently, the system covers 30 of China’s top 100 hospitals and a cumulative total of 300 hospitals rated at Grade II Class A or above.

Wang Jian also introduced the concept that “proactive healthcare redefines follow-up care.” “In traditional doctor-patient services, physicians’ medical practices were passive; doctors would only address issues when patients sought their help. In contrast, follow-up care embodies proactive healthcare services, wherein physicians proactively manage and monitor patients’ conditions based on their clinical needs. This approach facilitates early detection, early intervention, and early treatment, thereby enhancing healthcare quality and improving the precision of clinical diagnosis and management.”

This round of financing will be used for the knowledge base and technical upgrades of the core product, the AI Jishi Brain, and to rapidly establish technological and industrial synergy with iFlytek.

Sherpa Healthcare Partners, established in 2018, focuses on healthcare and medical projects with high-growth potential that are based in China or closely tied to local Chinese applications. These investments span, but are not limited to, pharmaceuticals, medical devices, healthcare services, and internet and technology solutions related to the healthcare sector.

Strategic Investors in This Round. Adhering to the investment philosophy of “Industry + Technology + Capital,” iFlytek Ventures is a venture capital platform focused on artificial intelligence-related fields. Its investment portfolio includes numerous well-known enterprises such as UBTECH, Cambricon, SenseTime, and Mainline Technology. Leveraging iFlytek’s industrial experience and resource integration capabilities, iFlytek Ventures conducts enabling industrial ecosystem investments centered on core AI technologies and their applications in enterprise services, education, healthcare, smart automobiles, fintech, and consumption upgrading. The firm primarily targets high-quality early- to mid-stage startups.

Series A investors and additional investors in this round. Zhejiang Haibang Fenghua Investment Management has a capital scale of RMB 3 billion, has cumulatively invested in over 80 projects, and has facilitated more than 10 IPO or M&A exits. Its investment portfolio includes multiple listed companies such as Dian Diagnostics, Tigermed, Hexing Electrical, Konfoong Materials, and Ewell Technology. The firm primarily focuses on the sectors of biomedicine, artificial intelligence and big data, and high-end manufacturing.